JP2018513681A5 - - Google Patents

Download PDF

Info

Publication number
JP2018513681A5
JP2018513681A5 JP2017552079A JP2017552079A JP2018513681A5 JP 2018513681 A5 JP2018513681 A5 JP 2018513681A5 JP 2017552079 A JP2017552079 A JP 2017552079A JP 2017552079 A JP2017552079 A JP 2017552079A JP 2018513681 A5 JP2018513681 A5 JP 2018513681A5
Authority
JP
Japan
Prior art keywords
protein
integrase
sequence
cas9
recombinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017552079A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018513681A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/025426 external-priority patent/WO2016161207A1/en
Publication of JP2018513681A publication Critical patent/JP2018513681A/ja
Publication of JP2018513681A5 publication Critical patent/JP2018513681A5/ja
Priority to JP2021110120A priority Critical patent/JP2021176301A/ja
Priority to JP2023121860A priority patent/JP7599740B2/ja
Priority to JP2024205951A priority patent/JP2025065094A/ja
Pending legal-status Critical Current

Links

JP2017552079A 2015-03-31 2016-03-31 細胞または生物のゲノムへのDNA配列の標的化組み込みのためのCas9レトロウイルスインテグラーゼおよびCas9レコンビナーゼ系 Pending JP2018513681A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021110120A JP2021176301A (ja) 2015-03-31 2021-07-01 細胞または生物のゲノムへのDNA配列の標的化組み込みのためのCas9レトロウイルスインテグラーゼおよびCas9レコンビナーゼ系
JP2023121860A JP7599740B2 (ja) 2015-03-31 2023-07-26 細胞または生物のゲノムへのDNA配列の標的化組み込みのためのCas9レトロウイルスインテグラーゼおよびCas9レコンビナーゼ系
JP2024205951A JP2025065094A (ja) 2015-03-31 2024-11-27 細胞または生物のゲノムへのDNA配列の標的化組み込みのためのCas9レトロウイルスインテグラーゼおよびCas9レコンビナーゼ系

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562140454P 2015-03-31 2015-03-31
US62/140,454 2015-03-31
US201562210451P 2015-08-27 2015-08-27
US62/210,451 2015-08-27
US201562240359P 2015-10-12 2015-10-12
US62/240,359 2015-10-12
PCT/US2016/025426 WO2016161207A1 (en) 2015-03-31 2016-03-31 Cas 9 retroviral integrase and cas 9 recombinase systems for targeted incorporation of a dna sequence into a genome of a cell or organism

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021110120A Division JP2021176301A (ja) 2015-03-31 2021-07-01 細胞または生物のゲノムへのDNA配列の標的化組み込みのためのCas9レトロウイルスインテグラーゼおよびCas9レコンビナーゼ系

Publications (2)

Publication Number Publication Date
JP2018513681A JP2018513681A (ja) 2018-05-31
JP2018513681A5 true JP2018513681A5 (enExample) 2019-05-09

Family

ID=55745849

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017552079A Pending JP2018513681A (ja) 2015-03-31 2016-03-31 細胞または生物のゲノムへのDNA配列の標的化組み込みのためのCas9レトロウイルスインテグラーゼおよびCas9レコンビナーゼ系
JP2021110120A Pending JP2021176301A (ja) 2015-03-31 2021-07-01 細胞または生物のゲノムへのDNA配列の標的化組み込みのためのCas9レトロウイルスインテグラーゼおよびCas9レコンビナーゼ系
JP2023121860A Active JP7599740B2 (ja) 2015-03-31 2023-07-26 細胞または生物のゲノムへのDNA配列の標的化組み込みのためのCas9レトロウイルスインテグラーゼおよびCas9レコンビナーゼ系
JP2024205951A Pending JP2025065094A (ja) 2015-03-31 2024-11-27 細胞または生物のゲノムへのDNA配列の標的化組み込みのためのCas9レトロウイルスインテグラーゼおよびCas9レコンビナーゼ系

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021110120A Pending JP2021176301A (ja) 2015-03-31 2021-07-01 細胞または生物のゲノムへのDNA配列の標的化組み込みのためのCas9レトロウイルスインテグラーゼおよびCas9レコンビナーゼ系
JP2023121860A Active JP7599740B2 (ja) 2015-03-31 2023-07-26 細胞または生物のゲノムへのDNA配列の標的化組み込みのためのCas9レトロウイルスインテグラーゼおよびCas9レコンビナーゼ系
JP2024205951A Pending JP2025065094A (ja) 2015-03-31 2024-11-27 細胞または生物のゲノムへのDNA配列の標的化組み込みのためのCas9レトロウイルスインテグラーゼおよびCas9レコンビナーゼ系

Country Status (8)

Country Link
US (2) US20180080051A1 (enExample)
EP (2) EP3277805B1 (enExample)
JP (4) JP2018513681A (enExample)
KR (3) KR102769515B1 (enExample)
CN (1) CN108124453B (enExample)
DK (1) DK3277805T3 (enExample)
ES (1) ES3030433T3 (enExample)
WO (1) WO2016161207A1 (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013066438A2 (en) 2011-07-22 2013-05-10 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
WO2016073990A2 (en) 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing
EP3277805B1 (en) * 2015-03-31 2025-05-07 SOHM, Inc. Cas 9 retroviral integrase systems for targeted incorporation of a dna sequence into a genome of a cell
EP3294896A1 (en) 2015-05-11 2018-03-21 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells
KR102796744B1 (ko) 2015-06-09 2025-04-15 에디타스 메디신, 인코포레이티드 이식의 개선을 위한 crispr/cas-관련 방법 및 조성물
EP3353296B1 (en) 2015-09-24 2020-11-04 Editas Medicine, Inc. Use of exonucleases to improve crispr/cas-mediated genome editing
SG10202104041PA (en) 2015-10-23 2021-06-29 Harvard College Nucleobase editors and uses thereof
US11597924B2 (en) 2016-03-25 2023-03-07 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
WO2017180694A1 (en) 2016-04-13 2017-10-19 Editas Medicine, Inc. Cas9 fusion molecules gene editing systems, and methods of use thereof
GB201610041D0 (en) * 2016-06-08 2016-07-20 Oxford Genetics Ltd Methods
KR20250103795A (ko) 2016-08-03 2025-07-07 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US12188059B2 (en) 2016-09-13 2025-01-07 The Broad Institute, Inc. Proximity-dependent biotinylation and uses thereof
CA3039409A1 (en) 2016-10-07 2018-04-12 Integrated Dna Technologies, Inc. S. pyogenes cas9 mutant genes and polypeptides encoded by same
US11242542B2 (en) 2016-10-07 2022-02-08 Integrated Dna Technologies, Inc. S. pyogenes Cas9 mutant genes and polypeptides encoded by same
SG11201903089RA (en) 2016-10-14 2019-05-30 Harvard College Aav delivery of nucleobase editors
AU2017364084B2 (en) * 2016-11-22 2024-07-04 Integrated Dna Technologies, Inc. CRISPR/Cpf1 systems and methods
US11293022B2 (en) 2016-12-12 2022-04-05 Integrated Dna Technologies, Inc. Genome editing enhancement
US11278570B2 (en) 2016-12-16 2022-03-22 B-Mogen Biotechnologies, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
KR102523318B1 (ko) 2016-12-16 2023-04-18 비-모젠 바이오테크놀로지스, 인크. 증진된 hAT 패밀리 트랜스포존 매개 유전자 전달 및 연관된 조성물, 시스템, 및 방법
WO2018119010A1 (en) 2016-12-19 2018-06-28 Editas Medicine, Inc. Assessing nuclease cleavage
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
EP3565907B1 (en) 2017-01-06 2022-05-04 Editas Medicine, Inc. Methods of assessing nuclease cleavage
EP3592381A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Cancer vaccine
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
WO2018165629A1 (en) 2017-03-10 2018-09-13 President And Fellows Of Harvard College Cytosine to guanine base editor
WO2018176009A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
US11499151B2 (en) 2017-04-28 2022-11-15 Editas Medicine, Inc. Methods and systems for analyzing guide RNA molecules
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
JP7518620B2 (ja) 2017-06-09 2024-07-18 エディタス・メディシン,インコーポレイテッド 操作されたcas9ヌクレアーゼ
US10392616B2 (en) 2017-06-30 2019-08-27 Arbor Biotechnologies, Inc. CRISPR RNA targeting enzymes and systems and uses thereof
BR112020000310A2 (pt) * 2017-07-07 2020-07-14 Toolgen Incorporated variantes de crispr alvo específicas
WO2019014564A1 (en) 2017-07-14 2019-01-17 Editas Medicine, Inc. SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
WO2019090173A1 (en) * 2017-11-02 2019-05-09 Arbor Biotechnologies, Inc. Novel crispr-associated transposon systems and components
WO2019118949A1 (en) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
JP2021527427A (ja) 2018-06-21 2021-10-14 ビー−モーゲン・バイオテクノロジーズ,インコーポレーテッド 強化されたhATファミリーのトランスポゾンが介在する遺伝子導入ならびに関連する組成物、システム、及び方法
AU2019291918B2 (en) 2018-06-29 2025-06-12 Editas Medicine, Inc. Synthetic guide molecules, compositions and methods relating thereto
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
CN113302291B (zh) * 2018-10-22 2025-04-18 罗切斯特大学 使用逆转录病毒整合酶-Cas9融合蛋白通过定向非同源DNA插入进行的基因组编辑
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
AU2019406778A1 (en) 2018-12-17 2021-07-22 Massachusetts Institute Of Technology Crispr-associated transposase systems and methods of use thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
AU2020228028A1 (en) * 2019-02-25 2021-09-30 University Of Massachusetts DNA-binding domain transactivators and uses thereof
EP3935179A4 (en) * 2019-03-07 2022-11-23 The Trustees of Columbia University in the City of New York RNA-GUIDED DNA INTEGRATION USING TN7-LIKE TRANSPOSONS
EP3942043A2 (en) 2019-03-19 2022-01-26 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
WO2020237208A1 (en) 2019-05-23 2020-11-26 Christiana Care Health Services, Inc. Gene knockout of variant nrf2 for treatment of cancer
CN114127291A (zh) * 2019-05-23 2022-03-01 克里斯蒂安娜保健服务公司 用于治疗癌症的nrf2基因敲除
WO2020243085A1 (en) * 2019-05-24 2020-12-03 The Trustees Of Columbia University In The City Of New York Engineered cas-transposon system for programmable and site-directed dna transpositions
AU2020290790B2 (en) * 2019-06-11 2026-02-19 Universitat Pompeu Fabra Targeted gene editing constructs and methods of using the same
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
US20220403357A1 (en) * 2019-11-12 2022-12-22 The Broad Institute, Inc. Small type ii cas proteins and methods of use thereof
WO2021216503A1 (en) * 2020-04-20 2021-10-28 Christiana Care Health Services, Inc. Aav delivery system for lung cancer treatment
BR112022022603A2 (pt) 2020-05-08 2023-01-17 Broad Inst Inc Métodos e composições para edição simultânea de ambas as fitas de sequência alvo de nucleotídeos de fita dupla
KR102679172B1 (ko) * 2020-07-06 2024-06-28 한국과학기술연구원 질환 세포-특이적인 miRNA에 의해 세포 생리 활성 조절 물질의 활성을 조절하는 복합체 및 이를 CRISPR/Cas 시스템에 적용한 질환 특이적 유전자 조작용 복합체
CN113913405B (zh) * 2020-07-10 2025-11-07 中国科学院动物研究所 一种编辑核酸的系统及方法
EP4185303A4 (en) * 2020-07-24 2024-10-30 University of Massachusetts Dna-binding domain transactivators and uses thereof
CN112159822A (zh) * 2020-09-30 2021-01-01 扬州大学 一种PS转座酶与CRISPR/dCpf1融合蛋白表达载体及其介导的定点整合方法
KR102803305B1 (ko) * 2020-11-25 2025-05-07 연세대학교 산학협력단 트랜스-스플라이싱 아데노-연관 바이러스 벡터를 포함하는 프라임에디팅용 조성물
CA3202411A1 (en) * 2020-12-16 2022-06-23 Marc Guell Cargol Therapeutic lama2 payload for treatment of congenital muscular dystrophy
JP2023554504A (ja) * 2020-12-16 2023-12-27 ユニバーシタット ポンペウ ファブラ プログラム可能なトランスポザーゼおよびその使用
CN121712899A (zh) * 2023-04-27 2026-03-20 伦斯勒理工学院 用于在真核细胞中准确插入dna序列的重组酶
CN118497204B (zh) * 2024-07-16 2024-12-03 西北农林科技大学深圳研究院 一种质粒CRISPR-pCas9n及基因编辑的方法与应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0871711A1 (en) * 1995-12-01 1998-10-21 The Regents Of The University Of California Compositions and methods for site-directed integration into dna
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
AU746454B2 (en) 1998-03-02 2002-05-02 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US20040003420A1 (en) 2000-11-10 2004-01-01 Ralf Kuhn Modified recombinase
GB0400814D0 (en) 2004-01-14 2004-02-18 Ark Therapeutics Ltd Integrating gene therapy vector
US20060252140A1 (en) * 2005-04-29 2006-11-09 Yant Stephen R Development of a transposon system for site-specific DNA integration in mammalian cells
ES2465996T3 (es) 2006-05-25 2014-06-09 Sangamo Biosciences, Inc. Métodos y composiciones para la inactivación genética
ES2586210T3 (es) 2006-12-14 2016-10-13 Sangamo Biosciences, Inc. Proteínas de dedo de zinc no canónicas optimizadas
US8816153B2 (en) 2010-08-27 2014-08-26 Monsanto Technology Llc Recombinant DNA constructs employing site-specific recombination
LT3401400T (lt) 2012-05-25 2019-06-10 The Regents Of The University Of California Būdai ir kompozicijos, skirtos rnr molekulės nukreipiamai tikslinės dnr modifikacijai ir rnr molekulės nukreipiamam transkripcijos moduliavimui
CN103668470B (zh) 2012-09-12 2015-07-29 上海斯丹赛生物技术有限公司 一种dna文库及构建转录激活子样效应因子核酸酶质粒的方法
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US9708589B2 (en) * 2012-12-18 2017-07-18 Monsanto Technology Llc Compositions and methods for custom site-specific DNA recombinases
US9393257B2 (en) 2013-03-01 2016-07-19 Regents Of The University Of Minnesota TALEN-based gene correction
SG11201507378UA (en) 2013-03-14 2015-10-29 Caribou Biosciences Inc Compositions and methods of nucleic acid-targeting nucleic acids
CA2910427C (en) 2013-05-10 2024-02-20 Sangamo Biosciences, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
EP3004339B1 (en) * 2013-05-29 2021-07-07 Cellectis New compact scaffold of cas9 in the type ii crispr system
DK3309248T3 (da) * 2013-05-29 2021-08-02 Cellectis Fremgangsmåde til manipulering af T-celler til immunterapi under anvendelse af et RNA-guidet CAS-nuklease-system
US9388430B2 (en) * 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
CN104404036B (zh) * 2014-11-03 2017-12-01 赛业(苏州)生物科技有限公司 基于CRISPR/Cas9技术的条件性基因敲除方法
EP3277805B1 (en) * 2015-03-31 2025-05-07 SOHM, Inc. Cas 9 retroviral integrase systems for targeted incorporation of a dna sequence into a genome of a cell
US9790490B2 (en) * 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems

Similar Documents

Publication Publication Date Title
ES2962434T3 (es) Procedimientos y composiciones para editar ARN
JP7698828B2 (ja) Rnaを編集する方法および組成物
Li et al. A potent Cas9-derived gene activator for plant and mammalian cells
Apolonia The old and the new: prospects for non-integrating lentiviral vector technology
Lewinski et al. Retroviral DNA integration—mechanism and consequences
JP2017018125A5 (enExample)
EP4600366A3 (en) Cas 9 retroviral integrase systems for targeted incorporation of a dna sequence into a genome of a cell
US9567603B2 (en) Using RNA-guided FokI nucleases (RFNs) to increase specificity for RNA-guided genome editing
IL309801B2 (en) Using nucleosome interacting protein domains to enhance targeted genome modification
JP2021526858A5 (enExample)
UA118014C2 (uk) Спосіб модифікації днк-мішені
JP2018522566A5 (enExample)
JP2016539629A5 (enExample)
JP2021534798A5 (enExample)
JP2014511698A5 (enExample)
JP2015171384A5 (enExample)
MX2018000729A (es) Métodos para amplificar las secuencias de ácido nucleico.
JP2013544511A5 (enExample)
RU2014138491A (ru) Композиции и способы лечения гемоглобинопатии
EP4372091A3 (en) Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides
JP2016537008A5 (enExample)
MX2021004714A (es) Proteina cas9 modificada, y uso de la misma.
JP2019536462A5 (enExample)
WO2007133674A3 (en) Lentiviral vector compositions, methods and applications
El Ashkar et al. Engineering next-generation BET-independent MLV vectors for safer gene therapy